ABVX
Abivax SA Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Other
- Website abivax.com
- Employees(FY) 26
- ISIN US00370M1036
Performance
-4.8%
1W
-3.9%
1M
+15.44%
3M
+39.86%
6M
+33.46%
YTD
+72.05%
1Y
Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Investment Analysis Report: ABVX
Overview
ABVX is a pharmaceutical company operating in the Health Technology sector. The company has shown significant fluctuations in its financial performance over the past three years. In this report, we will analyze ABVX's financial health, earnings and revenue growth, profitability, operating margin, operati...
Technical Analysis of ABVX 2024-05-03
Overview:
In analyzing the technical indicators for ABVX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your invest...
Recent News & Updates
- 2024-05-07 14:30
- 2024-05-07 04:00
- 2024-04-05 04:00
- 2024-04-01 14:30
Abivax reports 2023 financial results and operational update(Globenewswire)
- 2024-02-13 02:50
- 2024-02-12 13:50
- 2024-02-06 13:30
- 2024-02-01 13:30
- 2024-01-23 13:30
- 2024-01-21 13:30
- 2024-01-03 13:30
Abivax 2024 Financial Communication Calendar(globenewswire)
- 2023-11-20 13:30
Abivax announces the resumption of its liquidity contract(globenewswire)
- 2023-11-13 19:00
- 2023-10-24 16:15
Page 1 of 1
previousnext